Simvastatin Tablet, Film Coated
Product Images NDC 70518-3349

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Simvastatin (NDC 70518-3349). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Simvastatin is a prescription-only medication that is produced by Lupin Ltd in India. It is recommended to keep this medication out of reach of children. The package insert should be referred to for directions of use. The medication should be stored at a temperature between 20-26°C with occasional excursions permitted up to 15-30°C. This specific package of Simvastatin has been repackaged by RemedyRepack Inc in Indiana.*
FDA Label Image

Mm2 (Simvastatin 40mg 70518 3349 01)

Mm2 (Simvastatin 40mg 70518 3349 01)
Simvastatin is a prescription drug manufactured by Lupin Ltd in India that is used to lower cholesterol levels. The medication comes in tablet form and needs to be stored at room temperature, with excursions permitted to certain temperatures. The package insert has directions for use, and patients should keep the drug out of the reach of children. The drug's expiration date and lot number are also listed, and it has been repackaged by RemedyRepack Inc.*
FDA Label Image

Fig01 (Ae7ee793 92ec 44e2 85d2 33a672edd54e 01)

FDA Label Image

Fig1 (Ae7ee793 92ec 44e2 85d2 33a672edd54e 02)

Fig1 (Ae7ee793 92ec 44e2 85d2 33a672edd54e 02)
This text describes the results of a study on the effect of treatment with Simvastatin on major vascular events and major coronary events in HPS. The results are presented in a table format with the characteristics of the patients, such as age, gender, LDL, HDL-cholesterol, and incidence of events, along with the corresponding risk ratio. The study involved patients with and without CHD, diabetes mellitus, peripheral vascular disease, and cerebrovascular disease. The results show that Simvastatin treatment reduced the incidence of major vascular and coronary events in comparison to the placebo group across all patient characteristics except for those with diabetes mellitus, where the effects of the treatment were more limited.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.